JonesTrading has initiated coverage on shares of Evaxion A/S (NASDAQ:EVAX), issuing a buy rating along with a price target of $10.00, according to a report released on Tuesday. This development highlights growing interest in the clinical-stage biotechnology company, which specializes in immunotherapy and vaccine development driven by artificial intelligence.
Recent Analyst Ratings Impacting Evaxion
Other research firms have also recently provided their outlook on Evaxion A/S. On Monday, Lake Street Capital revised its price target for the company, lowering it from $11.00 to $9.00 while maintaining a buy rating. Meanwhile, Maxim Group began coverage on February 19, 2024, also issuing a buy rating with a price objective of $10.00.
Additionally, HC Wainwright reiterated a buy rating and set a target price of $16.00 for Evaxion’s shares, reflecting confidence in the company’s potential. In contrast, Weiss Ratings issued a sell (d-) rating on January 9, 2024. According to MarketBeat.com, the stock currently has an average rating of Moderate Buy with an average price target of $11.00.
Stock Performance and Institutional Investments
Evaxion A/S shares experienced an increase of 8.0% following the announcement of its quarterly earnings on March 5, 2024, during which the company reported an earnings per share (EPS) of $0.30. Analysts predict that Evaxion will post an EPS of -0.15 for the current year.
Recent institutional activity indicates a rising interest in Evaxion. Wesbanco Bank Inc. acquired a new stake valued at $48,000 in the fourth quarter, while Northwestern Mutual Wealth Management Co. invested $38,000. SmartHarvest Portfolios LLC also entered into a new position with an investment of $72,000. Overall, institutional investors now hold 11.04% of the company’s stock.
Evaxion A/S operates out of Copenhagen, Denmark, with additional activities in the United States. The company focuses on developing innovative immunotherapies and vaccines using its proprietary AI-based computational immunology platform. By harnessing machine learning and deep learning algorithms, Evaxion aims to identify and optimize antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.
Central to Evaxion’s strategy is its AI platform, which analyzes extensive datasets of genomic, proteomic, and immunological information to predict immune-stimulating epitopes, positioning the company at the forefront of biotechnological advancements.
For ongoing updates and insights on Evaxion A/S, investors can subscribe to daily summaries from MarketBeat.com.
